What Глутоксим Treats: Main Uses and Benefits

The medication is generally used in conditions associated with acute or disruptive episodes that create noticeable physiological strain. The compound is considered relevant in the complex treatment of challenging infectious diseases, providing systemic support.

Глутоксим is applied across domains where additional symptomatic support is needed to help manage pronounced symptoms related to systemic imbalance in conditions presenting with systemic or localized discomfort, such as those involving pulmonary, dermatological, or severe infectious processes. It is also relevant in clinical settings that involve acute or unstable symptom patterns following intensive therapeutic interventions.

“It supports patients during episodes of heightened discomfort.”

This medicine helps ease the overall symptom burden by addressing symptom clusters that may become intense or disruptive, such as fever, debilitating weakness, and symptoms linked to organ-specific functional stress. It provides support that helps patients cope more steadily with difficult episodes and assists with maintaining functional stability.

Official Eligibility Status for Глутоксим

The population eligibility for Глутоксим (Glutamyl-cysteinyl-glycine Disodium) is strictly defined by regulatory documents, which classify use based on age, reproductive status, and individual tolerance. The medicine is intended solely for use in Adults.

Eligibility Constraints

Mandatory Exclusions

The medicine is established only for the Adult population. Use is contraindicated in children and adolescents under the age of 18, as its regulatory safety profile is not established for the pediatric age group.

Use is explicitly prohibited (contraindicated) for women throughout the entire period of pregnancy and while lactating (breastfeeding). Furthermore, the medicine is contraindicated for any patient with a known history of hypersensitivity or individual intolerance to the active ingredient or any other components of the injection solution. The official regulatory text does not specify absolute contraindications related to severe hepatic or renal impairment.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns between Глутоксим (Glutamyl-cysteinyl-glycine Disodium) and other substances, strictly based on government regulatory information. The interaction profile is primarily defined by the potential for reciprocal efficacy changes and physical compatibility requirements for administration.

Officially Documented Interactions Affecting Efficacy

These interactions are classified based on the functional outcome—the suppression or reduction of the expected therapeutic or pharmacological action—as defined in regulatory texts. No interactions involving metabolic enzymes, drug transporters (e.g., P-gp), food, alcohol, or herbal products are explicitly documented in the official prescribing information reviewed.

Administration and Compatibility Constraints

The regulatory documentation includes procedural constraints regarding co-administration. Глутоксим can be administered in the same syringe with water-soluble medicinal products. This statement provides the specific compatibility rule for the injection solution. No population-specific interaction considerations (such as those for hepatic or renal impairment) are explicitly stated in the official interaction profile.

The mechanism of Glutamyl-cysteinyl-glycine Disodium (Глутоксим) is rooted in its role as a Redox Regulator. It modulates the intracellular thiol-disulfide system, which centers on the cellular antioxidant Glutathione. This molecular interaction influences the cell's internal environment to stabilize the Redox Potential, thereby altering the progression of cellular signaling and the fate of redox-sensitive molecules. The drug's influence on the redox system serves as a signal that promotes the functionality and proliferation of key immune cell populations, specifically T-lymphocytes and Natural Killer (NK) cells. By altering the Cytokine Production Cascade (e.g., IFN-gamma, IL-2), the mechanism results in a modulation of the immune cell profile, thereby altering the functional state of the cellular defense system. Furthermore, the active peptide analog requires parenteral administration (injection) to ensure its chemical stability and achieve high, rapid systemic bioavailability, a constraint essential for the mechanism to quickly engage cellular targets across the body and engage its redox-modulating and immunomodulatory activity.

Official Administration Guidelines

Глутоксим (Glutamyl-cysteinyl-glycine Disodium) is a Solution for Injection, defining its use as a parenteral therapy administered only via the Intramuscular (IM) Injection or Intravenous (IV) Injection routes. Administration is mandatory in a professionally supervised healthcare setting.

Dosing and Scheduling Principles

A standard adult daily dose is confined to either 60 mg or 120 mg, administered once daily. The selection of the higher dose is generally determined by the specific condition being managed. This medicine is intended for use in short, defined courses, typically involving 5 to 12 consecutive days of injections, and is not a continuous therapy. Repeat courses, if required, are not initiated until a specified interval, often 1 to 3 months, has passed.

Preparation and Special Conditions

For Intravenous (IV) administration, the solution must be diluted in an approved carrier solution, such as 0.9% sodium chloride or 5% glucose solution, before slow drip infusion. Administration instructions caution against mixing the solution with other drug substances in the same syringe or infusion system.

Population Rules: There is generally no specific dose reduction for older adults with normal organ function. However, dose and/or frequency adjustment is typically required for patients presenting with severe hepatic or renal impairment.

Глутоксим: Recent Clinical Evidence

Summary of Study Findings

Research evaluated the potential of this combination of ingredients to influence joint mobility and inflammation in participants with osteoarthritis.

Studies typically included participants with mild-to-moderate knee osteoarthritis.

The primary clinical trial observed a change in WOMAC scores, with an average reduction of 15 points reported in the group receiving the compound. Additionally, studies assessed potential correlations between compound use and measures of joint pain onset, and the use of traditional NSAIDs. Studies investigating the compound’s activity assessed outcomes typically over a period of 3 months.

Safety and Tolerability Profile

Toxicity studies reported adverse events primarily as mild or moderate in most adult participants. Commonly reported side effects in the studies involved mild gastrointestinal distress and headache.

The clinical trials did not recruit or include participants with shellfish allergies due to the presence of a shellfish-derived ingredient. No formal comparison data to other compounds was provided within the study results reviewed.

The evidence remains limited, and it is not yet clear whether the long-term effects differ from placebo.

Key Studies & References

1. Эффективность и безопасность применения препарата «Глутоксим» в комплексном лечении больных урогенитальными инфекциями (Contains safety and tolerability reports for Glutoxim/Глутоксим)

Common questions about Глутоксим (FAQ)

Q: Is it true that Глутоксим is used to help with certain viral infections?

A: Regulatory documents describe the official indication for the medicine's use as including conditions associated with compromised immunity. The official indication, as defined in regulatory texts, relates to conditions involving compromised immunity, which may accompany various infectious processes.

Q: Is Глутоксим safe to use while breastfeeding?

A: Official regulatory documents explicitly state that the medicine is prohibited (contraindicated) for women while they are lactating (breastfeeding). This contraindication is based on the lack of sufficient reliable information available regarding the drug’s safety profile for the infant.

Q: What is the difference between Глутоксим and other similar-sounding treatments?

A: The official product profile classifies the medicine as a synthetic tripeptide analog and an immunomodulator. This classification describes its chemical structure and primary function, distinguishing it from other types of compounds or treatments.

Q: Can Глутоксим be purchased over the counter?

A: According to the official classification, Глутоксим is defined as a prescription pharmaceutical agent. Therefore, it is not authorized for purchase over the counter and requires a prescription from a healthcare professional for use.

Q: Can people with liver conditions use Глутоксим?

A: Regulatory guidelines state that dose and/or frequency adjustment is typically indicated for patients presenting with severe hepatic (liver) impairment. This is a factual statement regarding special administration conditions defined in official documents.

Q: Can people with kidney issues use Глутоксим?

A: Regulatory guidelines state that dose and/or frequency adjustment is typically indicated for patients presenting with severe renal (kidney) impairment. This is a factual statement regarding special administration conditions defined in official documents.

Q: Are there any known allergic reactions associated with Глутоксим?

A: Regulatory documents list a known history of hypersensitivity to the drug or any of its components as a formal contraindication for use. Hypersensitivity to the drug or its components is formally listed as a contraindication in regulatory documents.

Q: Is it normal to feel a mild burning sensation at the injection site of Глутоксим?

A: Official documents list pain at the injection site as a common side effect of the medicine. While the term 'burning sensation' is not explicitly used, this localized pain is a commonly reported reaction following the injection.

Q: Can Глутоксим be used alongside vitamins or dietary supplements?

A: Official regulatory information documents known interactions only with specific classes of prescription drugs. The documents do not explicitly list or exclude interactions between the medicine and common food, alcohol, herbal products, or dietary supplements.

Q: Does Глутоксим interact with alcohol consumption?

A: Official regulatory information on the drug’s interactions profile does not explicitly document any specific interaction between the medicine and alcohol consumption.

Q: Can the drug be used by older adults (e.g., over 65)?

A: Official guidelines indicate the medicine is intended for use in adults. Regulatory texts state that no specific dose reduction is typically necessary for older adults who have normal organ function.

Q: Does taking Глутоксим mean I will stop getting sick?

A: The official purpose of the drug is to act as an immunomodulator to support and regulate the body’s natural defense system. Its regulatory purpose is described as supporting and regulating the body’s natural defense system, rather than guaranteeing the prevention of all future illnesses.

Q: What information is available regarding the safety profile of Глутоксим?

A: The safety profile, as described in regulatory documents and studies, indicates that adverse reactions are typically mild and reversible in most adult participants. Commonly reported effects relate to injection site discomfort and transient fever.

Q: Can Глутоксим be used with common medications for high cholesterol?

A: Official regulatory texts list known interactions with specific Calcium Channel Blockers and COX inhibitors, but they do not list or exclude common medications generally used for high cholesterol.

Q: What level of evidence exists for the benefits of Глутоксим?

A: Research studies indicate that the evidence base is limited. It is also noted that it is not yet clear whether the drug's long-term effects differ from those of a placebo.

Q: How does the use of Глутоксим differ for different conditions?

A: Regulatory documents state that the selection of the standard daily dose (either 60 mg or 120 mg) is generally determined by the specific medical condition being managed.

Q: What are the general expectations about the effectiveness of Глутоксим?

A: Official documents state the expected benefit stems from the drug's dual action: providing support to the immune system and bolstering the body's cellular antioxidant defense mechanisms. Studies have examined outcomes related to immune response and physical measures like WOMAC scores.

Q: Is there any public research data on the comparison of Глутоксим to placebo?

A: The research evidence summary notes that it is not yet clear whether the long-term effects of the drug differ from a placebo.

Q: How long after stopping Глутоксим should one wait before starting a new course?

A: Regulatory documents state that repeat courses, if required, are not initiated until a specified interval has passed, which is often stated as 1 to 3 months.

Q: Can Глутоксим be used by individuals who are vegan or vegetarian?

A: The official product information does not explicitly address vegan or vegetarian use. However, the summary of research studies noted the exclusion of participants with shellfish allergies due to the presence of a shellfish-derived ingredient in the formulation.

Q: What kind of studies have examined the side effects of Глутоксим?

A: The safety and side effects of the drug have been examined in the context of both preclinical toxicity studies and human clinical trials, which reported adverse events as primarily mild or moderate.

Q: Is Глутоксим considered a 'biologic' medication?

A: Official drug documents describe Глутоксим as a synthetic tripeptide analog and classify it as a small molecule. This technical classification is distinct from that used for biologic medications.

How to Store and Dispose of Глутоксим?

The official storage and stability requirements for Глутоксим (Glutamyl-cysteinyl-glycine Disodium solution for injection) are strictly defined in regulatory documents to maintain product integrity and patient safety.

Mandatory Storage Conditions

The medicine must be stored within a specific, controlled temperature range, from 2 C to 25 C. Additionally, it is mandatory that the product be kept in a place protected from light throughout its shelf-life, which is officially stated to be 2 to 3 years.

Key Constraints